Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 1999 April;40(2) > The Journal of Cardiovascular Surgery 1999 April;40(2):299-305

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

ORIGINAL ARTICLES  THORACIC PAPERS 

The Journal of Cardiovascular Surgery 1999 April;40(2):299-305

Copyright © 2000 EDIZIONI MINERVA MEDICA

language: English

Tumor markers kinetic in malignant lung neoplasms

Cristofori R., Aimo G. *, Mengozzi G. *, Oliaro A., Revello F. **, Rapellino M. **

From the Department of Thoracic Surgery S. Giovanni Battista Hospital, Turin, Italy University of Turin, Italy * Clinical Chemistry Laboratory ”Baldi e Riberi“ ** Department of Pathophysiology and Bronchoscopy


PDF


Background. No stud­ies ­about cor­re­la­tion ­between post­op­er­a­tive ­half-­life of ­tumor mark­ers and prog­no­sis in ­lung can­cer ­exist in lit­er­a­ture. The aim of our ­study was to deter­mine the ­half-­life of CEA, TPA, NSE and CYFRA 21-1 in post­op­er­a­tive peri­od ­after sur­gery of bron­cho­gen­ic car­ci­no­ma, and to cor­re­late it ­with the prog­no­sis and sur­vi­val of the ­patients.
Methods. From March 1997 to March 1998, 35 ­patients ­with bron­cho­gen­ic car­ci­no­ma ­were stud­ied (29 ­males and 6 ­females, ­mean age 64.9 ­years, ­range 51-77 and 61.0 ­years, ­range 52-77 respec­tive­ly). The ­mean fol­low-up for ­males was 125.70 ­days (­from 30 to 198) ­after sur­gery and for ­females 125.79 ­days (­from 30 to 180). CEA and NSE ­were test­ed by immu­noen­zy­mat­ic auto­mat­ed meth­od, where­as TPA and CYFRA 21-1 ­were ­assayed by immu­nor­a­di­o­met­ric tech­niques. For ­each ­patient ­both the dis­mis­sion ­curve and the ­half-­life of con­sid­ered mark­ers ­were cal­cu­lat­ed dur­ing fol­low-up.
Results. A sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence was ­found for pre­op­er­a­tive val­ues of TPA (p=0.027) and CYFRA 21-1 (p=0.025) ­between SqCLC and aden­o­car­cin­o­ma. The pre­op­er­a­tive lev­els of mark­ers ­were high­er in ­patients ­who ­would devel­ope a ­relapse, ­even if sta­tis­tical sig­ni-f­i­cance was not ­reached. CEA ­half-­life was of 1.4 ­days, ­while in ­patients ­with a histo­ry of ­relapse or met­a­static spread­ing was 4.5 ­days. No dif­fer­enc­es ­were ­revealed con­cern­ing CYFRA 21-1 ­between the two ­groups.
Conclusions. Seriate deter­mi­na­tion of ­some mark­ers (CEA and TPA in par­tic­u­lar) dur­ing post­op­er­a­tive fol­low-up ­after sur­gery for bron­cho­gen­ic car­ci­no­mas can be a use­ful prog­nos­tic ­tool. Longer fol­low-up ­would pro­vide addi­tion­al infor­ma­tions in ­order to deter­mine indi­vid­u­al pre­dic­tive thres­hold ­between ­poor and ­good prog­no­sis.

top of page